Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018

NEXT STORY
REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II
PREV STORY
Preexposure prophylaxis among LGBT youth
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress

- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod ...

author_avatar
NASDAQ Market News

Post-Hospital MRSA Infections Reduced By 30 Percent Through Use of Antiseptic Soap, Mouthwash, and Antibiotic Nasal Ointment

Rockville, Md., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Methicillin-resistant Staphylococcus aureus (MRSA) infections and ...

author_avatar
NASDAQ Market News